Key result
Supersaturated oxygen after anterior STEMI PCI meets FDA safety threshold with a ~7% event rate.
Why the study?
The safety of supersaturated oxygen (SSO2) therapy infused into the left main coronary after PCI for anterior STEMI was evaluated to address clinical concerns.
Absolute Event Rate: 7.1% vs 10.7%
Meets prespecified safety goal for post-PCI SSO2 in anterior STEMI; leaves open efficacy confirmation in randomized trials.
Key Points The intracoronary hyperoxemic oxygen therapy study, designed to demonstrate the safety of supersaturated oxygen (SSO2) infused into the left main coronary after percutaneous coronary intervention for anterior ST‐elevation myocardial infarction (STEMI), demonstrated a net adverse clinical event rate of 7.1%, lower than the Food and Drug Administration‐set goal of 10.7%. SSO2, which has reduced infarct size in clinical STEMI trials, might become an important strategy for treating anterior STEMIs. Larger postmarketing trials are needed to determine whether decreases in infarct size are observed in real‐world populations, whether they translate into improved clinical outcomes, and whether modifications in technique can streamline the administration of SSO2 therapy.
No takes yet. Share an insight, caveat, or question.
James C. Blankenship (2019) conducted an editorial in anterior ST-elevation myocardial infarction (STEMI). Supersaturated oxygen (SSO2) vs. FDA-set performance goal was evaluated on net adverse clinical event rate. Supersaturated oxygen infused after PCI for anterior STEMI resulted in a net adverse clinical event rate of 7.1%, which was lower than the FDA-set performance goal of 10.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: